Clincosm LogoSign in Get a demo

The Value of Tumor Feeding Vessels Deprivation Combined With Tyrosine Kinase Inhibitor in Liver Transplantation

Sponsor
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine (Other)
Overall Status
Recruiting
CT.gov ID
NCT05448339
Collaborator
(none)
35
Enrollment
1
Location
3
Anticipated Duration (Months)
11.7
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Abstract:To investigate the value of tumor feeding vessels deprivation combined with tyrosine kinase inhibitor in liver transplantation. A retrospective study was used to investigate patients who underwent liver transplantation from January 1, 2016 to December 31, 2019 in the Shanghai General Hospital. The patients were divided into two groups according to the downstaging therapy they underwent before transplantion.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    35 participants
    Observational Model:
    Case-Control
    Time Perspective:
    Prospective
    Official Title:
    The Value of Tumor Feeding Vessels Deprivation Combined With Tyrosine Kinase Inhibitor in Liver Transplantation
    Actual Study Start Date :
    Jun 1, 2022
    Anticipated Primary Completion Date :
    Aug 31, 2022
    Anticipated Study Completion Date :
    Aug 31, 2022

    Arms and Interventions

    Arm Intervention/Treatment
    PVHA

    Patients underwent tumor feeding vessels deprivation combined with tyrosine kinase inhibitor before liver transplantation
    TACE

    Patients underwent TACE therapy combined with tyrosine kinase inhibitor before liver transplantation

    Outcome Measures

    Primary Outcome Measures

    1. the value of tumor feeding vessels deprivation combined with tyrosine kinase inhibitor in liver transplantation [2016-2019]

      the value of tumor feeding vessels deprivation combined with tyrosine kinase inhibitor in liver transplantation

    Secondary Outcome Measures

    1. AFP reduction of patients [2016-2019]

      AFP reduction after tumor trophovascular deprivation combined with tyrosine kinase inhibitors.

    2. survival time of patients [2016-2019]

      the effect of tumor trophovascular deprivation combined with tyrosine kinase inhibitor treatment on the overall survival time of patients after transplantation

    3. the prognosis of patients [2016-2019]

      the prognosis of patients undergoing tumor trophovascular deprivation in combination with tyrosine kinase inhibitors

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 18 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    1. Voluntarily sign informed consent

    2. Patients whose preoperative pathological diagnosis of hepatocellular carcinoma exceeded the transplantation criteria

    3. Aged between 18 and 75

    4. No other treatment was performed

    Exclusion Criteria:

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 The value of tumor feeding vessels deprivation combined with tyrosine kinase inhibitor in liver transplantation: a randomized, controlled and retrospective study Shanghai Shanghai China 200000

    Sponsors and Collaborators

    • Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Lin Zhong, director, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
    ClinicalTrials.gov Identifier:
    NCT05448339
    Other Study ID Numbers:
    • SHLTQC-5
    First Posted:
    Jul 7, 2022
    Last Update Posted:
    Jul 7, 2022
    Last Verified:
    Jul 1, 2022
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No

    Study Results

    No Results Posted as of Jul 7, 2022